Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 5Venous Thromboembolism 3Venous Thrombosis 2Lung Neoplasms 2Thromboembolism 1Pulmonary Embolism 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Liver Diseases 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Sorafenib 5Blood Specimen Collection 4lenvatinib 3sintilimab 2pembrolizumab 2ledipasvir, sofosbuvir drug combination 2halofantrine 2camrelizumab 2atezolizumab 2Liver Transplantation 2Immunotherapy 2Control Groups 2Bevacizumab 2Antibodies 2veliparib 1trifluridine tipiracil drug combination 1trametinib 1toripalimab 1titanium silicide 1tislelizumab 1rubitecan 1repotrectinib 1pevonedistat 1ozanimod 1linifanib 1genexol-PM 1gadolinium ethoxybenzyl DTPA 1fluorocholine 1fisogatinib 1ficlatuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Diseases × Nadroparin × Clear all
NCT00827554 2016-04-01

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

Eastern Hepatobiliary Surgery Hospital

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡